A carregar...
New therapies for von Willebrand disease
The management of von Willebrand disease (VWD) is based upon the dual correction of the primary hemostasis defect, due to the inherited deficiency of von Willebrand factor (VWF), and of the secondary defect of factor VIII coagulant activity (FVIII:C), due to the loss of binding and stabilization by...
Na minha lista:
| Publicado no: | Blood Adv |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6855108/ https://ncbi.nlm.nih.gov/pubmed/31714963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000368 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|